Thomas Podsadecki

6.5k citations

72 papers · 4.2k indexed · 3 hit papers · h-index 28

Impact in

Hepatology top 0.1%
- Hepatitis C virus research
- Liver Disease and Transplantation
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Hepatology 50
- Hepatitis C virus research 50
Infectious Diseases 37
- HIV/AIDS drug development and treatment 37
- HIV/AIDS Research and Interventions 8

Co-authors: Barry Bernstein Lois Larsen Kris V. Kowdley Edward Tam Fred Poordad Daniel E. Cohen Rajeev Menon Junyuan Xiong
Journals: Journal of Hepatology (27 papers)Gastroenterology (7 papers)Antimicrobial Agents and Chemotherapy (5 papers)New England Journal of Medicine (5 papers)HIV Clinical Trials (4 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Thomas Podsadecki

70 papers receiving 4.1k citations

Hit Papers

align trajectories log scale

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis 2014 · 646 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 New England Journal of Medicine
2014 New England Journal of Medicine
2014 New England Journal of Medicine

Peers

Countries citing papers authored by Thomas Podsadecki

Since Specialization

Citations

This map shows the geographic impact of Thomas Podsadecki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Podsadecki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Podsadecki more than expected).

Fields of papers citing papers by Thomas Podsadecki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Podsadecki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Podsadecki. The network helps show where Thomas Podsadecki may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas Podsadecki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Podsadecki Line = papers co-authored together Thomas Podsadecki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Exposure–Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies Clinical Drug Investigation ·Chih‐Wei Lin, Rajeev Menon, Wei Liu, Thomas Podsadecki, Nancy S. Shulman, Kyryl Kazymyrenko, Walid M. Awni, Sandeep Dutta	2017	3
2	Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection The AAPS Journal ·Akshanth R. Polepally, Haoyu Wang, Patrick Marroum, Mukul Minocha, Balakrishna Hosmane, Amit Khatri, Sven Mensing, Thomas Podsadecki, Daniel E. Cohen, Walid M. Awni, Rajeev Menon	2017	1
3	Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors Clinical Infectious Diseases ·Amit Khatri, Sandeep Dutta, Haoyu Wang, Thomas Podsadecki, Roger Trinh, Walid M. Awni, Rajeev Menon	2016	28
4	Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients Clinical Drug Investigation ·Amit Khatri, Sven Mensing, Thomas Podsadecki, Walid M. Awni, Rajeev Menon, Sandeep Dutta	2016	3
5	Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers Clinical Pharmacokinetics ·Akshanth R. Polepally, Jennifer R. King, Сотова Юлия Ильинична, N.I. Guseynova, Emily O. Dumas, Amit Khatri, Yi‐Lin Chiu, Thomas Podsadecki, Rajeev Menon	2016	25
6	Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies The AAPS Journal ·Sven Mensing, Akshanth R. Polepally, Jason Whitesel, Amit Khatri, Wei Liu, Thomas Podsadecki, Walid M. Awni, Rajeev Menon, Sandeep Dutta	2015	11
7	SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin Hepatology ·Massimo Colombo, Ola Weiland, Daniel E. Cohen, Jean‐François Dufour, Hendrik Reynaert, M. Diago, Erica Villa, Adrian Streinu‐Cercel, Wangang Xie, Tolga Baykal, Jeffrey Enejosa, Eoin Coakley, Roger Trinh, Thomas Podsadecki	2014	2
8	Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin New England Journal of Medicine ·Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel H. Sigal, David R. Nelson, Dorothy H. Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Edward Tam, Kyryl Kazymyrenko, Lois Larsen, Thomas Podsadecki, Barry Bernstein Hit paper breakdown →	2014	686
9	ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection Gastroenterology ·Pietro Andreoné, Massimo Colombo, Jeffrey Enejosa, İftihar Köksal, Péter Ferenci, A Maieron, Beat Müllhaupt, Yves Horsmans, Ola Weiland, H. W. Reesink, Lino Rodrigues, Yiran Hu, Thomas Podsadecki, Barry Bernstein	2014	273
10	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 New England Journal of Medicine ·Kris V. Kowdley, Eric Lawitz, Fred Poordad, Daniel E. Cohen, David R. Nelson, Stefan Zeuzem, Gregory T. Everson, Paul Y. Kwo, Graham R. Foster, Mark Sulkowski, Wangang Xie, Edward Tam, Lokre, Lois Larsen, Amit Khatri, Thomas Podsadecki, Barry Bernstein	2014	185
11	Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin New England Journal of Medicine ·Stefan Zeuzem, Ira M. Jacobson, Tolga Baykal, Rui Tato Marinho, Fred Poordad, Marc Bourlière, Mark Sulkowski, Heiner Wedemeyer, Edward Tam, Paul Desmond, Donald M. Jensen, Adrian M. Di Bisceglie, Peter Varunok, Tarek Hassanein, Junyuan Xiong, Kyryl Kazymyrenko, Lois Larsen, Thomas Podsadecki, Barry Bernstein Hit paper breakdown →	2014	395
12	A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1 Journal of Hepatology ·Eric Lawitz, Fred Poordad, Kris V. Kowdley, Daniel E. Cohen, Thomas Podsadecki, Muhammad Jamshed, Lois Larsen, Rajeev Menon, Gennadiy Koev, Rakesh Tripathi, Edward Tam, Barry Bernstein	2013	55
13	Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study AIDS Research and Human Retroviruses ·Jacques Reynes, Roger Trinh, Federico Pulido, Ruth Soto-Malave, Joseph Gathe, Roula Qaqish, Min Tian, Linda Fredrick, Thomas Podsadecki, Michael Norton, Angela M. Nilius	2012	103
14	Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results HIV Clinical Trials ·Jacques Reynes, Payam R. Yashar, Federico Pulido, Ruth Soto-Malave, Joseph Gathe, Min Tian, Linda Fredrick, Thomas Podsadecki, Angela M. Nilius	2011	56
15	Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1–Infected Subjects at 48 Weeks JAIDS Journal of Acquired Immune Deficiency Syndromes ·Roberto Zajdenverg, Thomas Podsadecki, Sharlaa Badal‐Faesen, Jaime Andrade‐Villanueva, Joseph Gathe, Horacio Mingrone, Linda Fredrick, I Nyoman Theo Ardiles Rada, William C. Woodward, Barry Bernstein	2010	26
16	Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir The Journal of Clinical Pharmacology ·Cheri E. Klein, Yi‐Lin Chiu, Rosi Maria Koch, Maureen F. Caraker, Kathryn R. King, Scott J. Neary, Thao Doan, Dwiki Setya Hendrawan, Thomas Podsadecki, George J. Hanna	2008	36
17	“White Coat Compliance” Limits the Reliability of Therapeutic Drug Monitoring in HIV-1—Infected Patients HIV Clinical Trials ·Thomas Podsadecki, Bernard Vrijens, Eric Tousset, Richard A. Rode, George J. Hanna	2008	109
18	A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 Weeks AIDS Research and Human Retroviruses ·Jean‐Michel Molina, Thomas Podsadecki, Margaret Johnson, Aimee Wilkin, Peré Domingo, Robert A. Myers, 武司豊佳, Richard A. Rode, Martin King, George J. Hanna	2007	57
19	Substitution with Lopinavir/Ritonavir Improves Patient-Reported Outcomes Including Quality of Life in Patients Who Were Intolerant to Their Antiretroviral Therapy HIV Clinical Trials ·Eduardo Sprinz, Chang Kyo Shin, Matthew K. Goncharow, Delbert Mongan, Michelle P. Luo, Marcela Löflerová, 洋一郎池田, Kathryn R. King, Richard A. Rode, Scott C. Brun, George J. Hanna, Thomas Podsadecki	2006	10
20	Substitution with Lopinavir/Ritonavir Improves Patient-Reported Outcomes Including Quality of Life in Patients Who Were Intolerant to Their Antiretroviral Therapy HIV Clinical Trials ·Eduardo Sprinz, Christopher David Cassity, Matthew K. Goncharow, Stephen Green, Michelle Luo, Marcela Löflerová, 洋一郎池田, Kathryn King, Richard A. Rode, Scott Brun, George J. Hanna, Thomas Podsadecki	2006	2

About Thomas Podsadecki

Thomas Podsadecki is a scholar working on Hepatology, Infectious Diseases, Virology, Genetics and Epidemiology, having authored 72 papers that have together received 4.2k indexed citations. Recurring topics across this work include Hepatitis C virus research (50 papers), HIV/AIDS drug development and treatment (37 papers), Hepatitis B Virus Studies (19 papers), Liver Disease Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (10 papers), HIV Research and Treatment (9 papers), HIV/AIDS Research and Interventions (8 papers) and Systemic Lupus Erythematosus Research (8 papers). The work is most often cited by research in Hepatology (3.4k citations), Infectious Diseases (1.6k citations), Epidemiology (3.0k citations), Virology (402 citations) and Transplantation (75 citations). Thomas Podsadecki has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Barry Bernstein, Lois Larsen, Kris V. Kowdley, Edward Tam, Fred Poordad, Daniel E. Cohen, Rajeev Menon, Junyuan Xiong, Ola Weiland and Eoin Coakley. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Antimicrobial Agents and Chemotherapy, New England Journal of Medicine and HIV Clinical Trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact